Research Topics
| Ann S LaCasceSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Post-transplant lymphoproliferative disordersAnn S LaCasce
Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Oncologist 11:674-80. 2006..Prognosis is variable, due in part to the heterogeneity of the disease, which ranges from reactive plasmacytic hyperplasia to aggressive monoclonal disease...
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer NetworkAnn S LaCasce
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 26:5107-12. 2008..We sought to estimate the impact of expert review in the modern era by comparing final pathologic diagnoses at five comprehensive cancer centers with diagnoses assigned at referring centers...
Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapyGeorge P Canellos
Medical Oncology Hematology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 28:1611-5. 2010..This study examines the impact of chemotherapy alone in treatment of limited-stage, nonbulky HL, radiation therapy eliminated from primary treatment...- Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphomaAnn S LaCasce
Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
Semin Hematol 45:85-9. 2008..Until such trials are mature, we do not recommend using these agents in combination outside of the research setting... - Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients Yi Bin Chen
Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
Leuk Lymphoma 51:789-96. 2010..In conclusion, patients who fail R-CHOP appear to benefit from ASCT, but they may have a worse prognosis compared to patients who fail CHOP alone... - Primary mediastinal large B-cell lymphomaJason E Faris
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA
Clin Adv Hematol Oncol 7:125-33. 2009.... - Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disordersJennifer R Brown
Department of Medical Oncology, Dana Farber Cancer Institute, Dana Farber Cancer Institute, Boston, MA 02115, USA
Br J Haematol 143:361-8. 2008..026). We conclude that familial aggregation of LPDs is common among newly diagnosed patients, varies significantly by diagnosis and contributes meaningfully to the population disease burden... - Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysisAlfred Ian Lee
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
Cancer 116:3835-42. 2010..The majority of patients with Hodgkin lymphoma (HL) achieve disease remission after primary therapy. To the best of the authors' knowledge, no consensus exists for postremission surveillance imaging... - Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcomePhilippe Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 14:418-25. 2008..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population... - EnzastaurinYi Bin Chen
Dana Farber Cancer Institute, Massachusetts General Hospital, GRB 740, 44 Binney Street, Boston, MA 02115, USA
Expert Opin Investig Drugs 17:939-44. 2008..Enzastaurin is a novel antineoplastic and antiangiogenic agent that acts through inhibition of protein kinase C (PKC)... - Nodular lymphocyte predominant Hodgkin lymphomaAlfred Ian Lee
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Oncologist 14:739-51. 2009..For relapsed disease, treatment options include the salvage therapies used in classical HL, and rituximab... - Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes databaseMichelle E Kho
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 113:3209-12. 2008..Clinical trials and outcomes studies often rely on nonphysicians to abstract complex data from medical records, but the reliability of these data are rarely assessed... - Lymphoma: risk and response after solid organ transplantCaron A Jacobson
Division of Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Oncology (Williston Park) 24:936-44. 2010..Further clinical investigation, including randomized controlled trials, will be important in reaching this goal... - Non-Hodgkin's lymphomasAndrew D Zelenetz
J Natl Compr Canc Netw 6:356-421. 2008 - Non-Hodgkin's lymphoma. Clinical practice guidelines in oncologyAndrew D Zelenetz
J Natl Compr Canc Netw 4:258-310. 2006